Probe Development & Biomarker Exploration, Thunder Bay Regional Health Research Institute, Thunder Bay, ON, P7B 6V4, Canada.
Biotechnology Program, Lakehead University, Thunder Bay, ON, P7B 5E1, Canada.
Nanomedicine (Lond). 2018 Feb 1;13(4):455-474. doi: 10.2217/nnm-2017-0242. Epub 2018 Jan 31.
High-risk human papillomaviruses infect skin and mucosa, causing approximately 5% of cancers worldwide. In the search for targeted nanotherapeutic approaches, siRNAs against the viral E6 transcript have been molecules of interest but have not yet seen successful translation into the clinic. By reviewing the past approximately 15 years of in vitro literature, we identify the need for siRNA validation protocols which concurrently evaluate ranges of key treatment parameters as well as characterize downstream process restoration in a methodical, quantitative manner and demonstrate their implementation using our own data. We also reflect on the future need for more appropriate cell culture models to represent patient lesions as well as the application of personalized approaches to identify optimal treatment strategies.
高危型人乳头瘤病毒感染皮肤和黏膜，导致全球约 5%的癌症。在寻找靶向纳米治疗方法的过程中，针对病毒 E6 转录本的 siRNA 一直是人们关注的焦点，但尚未成功转化为临床应用。通过回顾过去大约 15 年的体外文献，我们发现需要 siRNA 验证方案，该方案需要同时评估一系列关键治疗参数，并以系统、定量的方式对下游过程的恢复进行特征描述，并使用我们自己的数据来证明其实施。我们还反思了未来对更合适的细胞培养模型的需求，以代表患者病变，以及应用个性化方法来确定最佳治疗策略的需求。
